Trial Profile
A study to evaluate the co-relation of expression levels of vascular endothelial growth factor C (VEGF-C) and SLUG to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs) resistance in lung cancer patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 01 Jun 2016
Price :
$35
*
At a glance
- Drugs Gefitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Pharmacodynamics
- 01 Jun 2016 New trial record